Molecular Biomarker Development & Assay Validation
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This subcontract with the National Institutes of Health under the Department of Health and Human Services focuses on the development, testing, and validation of molecular biomarkers for the early detection of pancreatic ductal adenocarcinoma. The selected provider will support prime contractors on research projects by developing assays to identify high-risk patients and performing validation studies utilizing mass spectrometry, PCR, and high-throughput sequencing. The project requires the delivery of validated molecular assays and comprehensive validation data reports. A critical requirement for the clinical validation phases is the possession of CLIA certification. This opportunity is categorized under NAICS code 621511 and has a response deadline of November 5, 2029.
General Info
Agency
Place of Performance
Not specifiedSet-Aside
Documents
This scope was carved out of PAR-28-056.
The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
